Trulicity
dulaglutide · GLP-1 receptor agonist
Trulicity is once-weekly dulaglutide, FDA-approved for type 2 diabetes in adults and children 10 and older, and for reducing cardiovascular risk. It is an older-generation GLP-1: reliable for blood sugar, modest for weight compared with semaglutide or tirzepatide. Its pen is the simplest to use in the class, with a hidden needle and no dose dialing. Doses step up from 0.75 mg to 4.5 mg. A boxed warning covers thyroid C-cell tumor risk. List price is roughly $987/mo, and supply of the 3 mg and 4.5 mg doses remains constrained.
GLP-1 RA
Once weekly
Modest (~3%)
$987/mo
Overview
Trulicity is the brand name for dulaglutide, a once-weekly injectable from Eli Lilly in the GLP-1 receptor agonist class. It launched in 2014, well before semaglutide and tirzepatide, and uses a prefilled pen with a hidden needle and no dose dialing that many people find the easiest GLP-1 to self-administer. It is FDA-approved to improve glycemic control in type 2 diabetes and to reduce cardiovascular events. It is not approved for weight loss, and its weight effect is meaningfully smaller than newer medications in the class.
How Trulicity works
Steadies blood sugar
Slows digestion
Lowers cardiovascular risk
What it's used for
- Improve blood sugar (A1C) in adults with type 2 diabetes
- Improve blood sugar in children 10 years and older with type 2 diabetes
- Reduce major cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors
- Not FDA-approved for weight loss
Effectiveness
Across the AWARD trials, Trulicity lowered A1C by roughly 0.7 to 1.5 points depending on dose and comparator. Mean weight loss was modest, generally around 2 to 3 kg, well below what semaglutide or tirzepatide achieve. In REWIND, it reduced major adverse cardiovascular events in a broad type 2 diabetes population that included people without prior cardiovascular disease, which is a wider population than most GLP-1 outcome trials enrolled. Individual results vary.
Dosing schedule
Unlike other GLP-1 pens, Trulicity requires no dose dialing and no needle handling. Each pen is preset to a single dose. Injection day can be changed as long as at least 3 days separate two doses.
Supply & availability
Trulicity has been on the FDA drug shortage list since August 2022, one of the longest-running prescription drug shortages in recent memory. The 3 mg and 4.5 mg doses are the most affected; the 0.75 mg and 1.5 mg doses are generally easier to fill. Eli Lilly has prioritised manufacturing capacity for tirzepatide, and no United States resolution date has been confirmed.
If you are starting or maintaining Trulicity, ask your pharmacy to check stock before your refill is due rather than on the day you run out. Some compounding pharmacies have produced dulaglutide products during the shortage; both Eli Lilly and the FDA have warned that these have not been reviewed for safety, quality, or effectiveness.
Side effects & Safety
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Abdominal pain
- Fatigue
Serious risks & warnings
- Thyroid C-cell tumor risk (boxed warning)
- Pancreatitis
- Gallbladder problems
- Low blood sugar with insulin/sulfonylureas
- Kidney injury from dehydration
- Severe gastrointestinal reactions
- Diabetic retinopathy changes
- Serious hypersensitivity reactions
Do not use with a personal or family history of medullary thyroid carcinoma or MEN 2.
Cost & savings
ist price is about $987/mo without insurance. Most people pay less through one of these routes:
Through insurance
As low as $25
Telehealth cash-pay
$99/mo
Patient assistance$0
The Trulicity Savings Card excludes Medicare, Medicaid, TRICARE, and VA beneficiaries. No generic or biosimilar dulaglutide exists. Prices verified August 2026 and subject to change.
Compare with other GLP-1s
Frequently asked questions
Does Trulicity cause weight loss?
Some, but much less than newer GLP-1 medications. Trial averages were roughly 2 to 3 kg. If weight loss is the primary goal, Trulicity is not the medication most clinicians would reach for.
Why is Trulicity hard to find?
It has been on the FDA drug shortage list since August 2022, with the higher 3 mg and 4.5 mg doses hit hardest. Eli Lilly has prioritised tirzepatide manufacturing, and no United States resolution date has been confirmed.
Is there a generic Trulicity?
No. No generic or biosimilar dulaglutide has been approved, and Eli Lilly's United States patent runs to at least 2027.
How does Trulicity compare to Ozempic?
Both are once-weekly GLP-1 injections for type 2 diabetes. Semaglutide generally produces larger A1C and weight reductions in head-to-head data. Trulicity's pen is simpler to use and requires no dose dialing.
Can children take Trulicity?
Yes. It is FDA-approved for type 2 diabetes in patients 10 years and older, which distinguishes it from most medications in this class.
Educational only, not medical advice. Trulicity is a prescription medication; a licensed clinician determines if it's appropriate. Effectiveness figures are trial averages (AWARD, REWIND); results vary. Trulicity is not FDA-approved for weight loss. Supply and pricing information verified August 2026 and subject to change. *Starting price for doctor-guided care; medication cost is separate.